Loading data for REVBW — first visit, this takes a few seconds.
Revelation Biosciences In... (REVBW)
NasdaqCM: REVBW
· Real-Time Price · USD
0.01
+0.00 (0.00%)
At close: Aug 24, 2026, 1:52 PM
The price, the headline numbers and the latest news, in one place.
Revelation Biosciences Inc. (REVBW) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.2M |
| -0.17 | |
| -4.77 | |
| n/a | |
| n/a | |
| P/B (ttm) | n/a |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 249 |
| Avg. Volume (20D) | |
| Open | 0.01 |
| Previous Close | 0.01 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.01 - 0.01 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About REVBW
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the ...
IPO Date Jul 17, 2026
Employees 8
Stock Exchange NasdaqCM
Ticker Symbol REVBW
Website https://www.revbiosciences.com
Financial Performance
In 2025, Revelation Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.91M, a decrease of -40.73%.
Financial Statements